PPII Coenzyme A Inc (CE)

Pro-Pointer, Inc. (PINKSHEETS: PPII), through its wholly owned subsidiary Coenzyme-A Technologies, Inc., is pleased to announce the release of its latest unique and innovative proprietary line of Cosmeceutical formulations the "SKIN-MATRIX™" Skin Treatment System. These proprietary products were developed according to the latest scientific Skin Anti-Aging research. The "SKIN-MATRIX™" products not only address nutritional deficiencies, environmental stress from Oxygen and Sunlight, including the biologically persistent ubiquitous toxins of pollution but also the Non Enzymatic Glycosylation processes that dramatically speed up the human skins aging process.

"The Uniqueness of the "SKIN-MATRIX™" development is derived from the functional properties of its own individual ingredients, in which upon blending undergo certain chemical reactions, thus creating a new synergistic Super Molecular Structure similar to the Extra Cellular Matrix of the Human Skin," stated Nickolaos D. Skouras, Ph.D., President /CEO of Coenzyme-A Technologies, Inc.

Presently the Global Cosmeceutical market well exceeds the 1 Billion Dollar value and is expected to grow well over two Billion Dollars by 2012. As 78 million Baby Boomers approach retirement age over the next decade, sales of Age Defying Skin and Hair care products, Energy boosting and Health promoting Nutraceuticals, and Weight Loss supplements are posed to take off.

Despite the overall national economic downturn, U.S. sales of Cosmeceuticals and OTC Cosmetics as means to prevent the aging process and to continue to look and feel young are at a constant rise.

The "SKIN-MATRIX™" line of Cosmeceuticals, being a very cost effective product line to manufacture since it requires "Liquid Technology," will produce unprecedented Monetary profit gains of up to 3,000%. This translates to gross annual sales of well over 4.5 million dollars.

During the past four years the "SKIN-MATRIX™" Cosmeceuticals have been successfully test-marketed nationally and internationally in a premium price bracket thus already successfully proving both their functional benefits and their monetary price effectiveness.

ABOUT COENZYME-A TECHNOLOGIES, INC. -- Coenzyme-A Technologies, Inc. is an innovative company that has applied new technology to the formulation and manufacture of a series of proprietary products which address nutritional deficiencies that result from the stress of modern day living, chemical imbalances within the body, and the deleterious effects of aging. Coenzyme-A is the first nutraceutical product to combine nutritional components that can be successfully used by the body to support its manufacture and utilization of cellular Coenzyme-A (The Master Coenzyme). Coenzyme-A contains a specific set of substrates that are designed to assist the body in converting fats, carbohydrates and proteins into energy at the cellular level. See Company website -- www.coenzyme-a.com

FORWARD-LOOKING STATEMENTS The information contained in this news release, other than historical information, consists of forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. Such forward-looking statements involve known and unknown risks and uncertainties, including all business uncertainties relating to product development, marketing, market acceptance, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

INVESTOR RELATIONS at: InvestSource, Inc. 6352 Santa Ynez Drive Huntington Beach, CA 92647 Phone (714)847-2460 Fax (714) 847-4987